A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
Clinical trial NCT06895512 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06895512
- Sponsor
- Shanghai Henlius Biotech
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-01
- Primary completion
- 2027-07-01
- Enrollment
- 386
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.